The $340 central target is the arithmetic mean of individual, verifiable analyst price targets collected from recent coverage of CI, rather than a single firm's figure or a website's headline consensus. More than a dozen current targets were reviewed, spanning roughly $290 to $400, and their mean came to about $339, which rounds to $340.
Views differ meaningfully across the Street. On the bullish side, Piper Sandler's Jessica Tassan raised her target to $370 in late October 2026, while Bernstein's Lance Wilkes raised his to $387 and Baird, Guggenheim, Goldman Sachs, and Oppenheimer hold targets in the $350–$365 area, citing Evernorth's growth and higher forward estimates. On the cautious side, Evercore ISI initiated coverage with an In Line rating and a $290 target in early October, while Deutsche Bank ($305) and Barclays ($303) sit closer to the current price. Jefferies cut its rating to Hold with a $307 target, and Raymond James trimmed its rating from Strong Buy to Outperform with a $320 target, reflecting concerns about valuation and regulatory risk. This spread explains why the consensus is best read as a midpoint rather than a precise forecast.
The latest verified price for The Cigna Group is about $298.23. Reaching $340 would require a move of roughly 14%, which qualifies as a substantial but not extreme advance for a large-cap stock. CI trades near a P/E (price-to-earnings) ratio of roughly 12 on trailing earnings and a single-digit forward multiple, below the broader market, and pays a dividend yield near 2%.
The stock climbed to a 52-week high near $316 in late October 2026 before a pullback on profit-taking and renewed policy headlines, so $340 sits above that recent peak but below the loftiest targets. A path to $340 would likely require continued EPS growth, sustained Evernorth momentum, and a re-rating as investors become more comfortable with the regulatory backdrop — rather than a single catalyst.
Several verified factors underpin the constructive case. Cigna reported second-quarter 2026 EPS of $6.29, up about 10% year over year, with revenue of roughly $71.7 billion, and its Evernorth Health Services segment — a large pharmacy benefit manager (PBM) and specialty-pharmacy operation — continues to drive growth through biosimilars and specialty programs. Management has targeted long-term annual EPS growth in the low double digits, supported by a sizable share-repurchase program. The company has also streamlined its portfolio by divesting lower-margin Medicare businesses to focus on employer-sponsored commercial coverage. A below-market valuation, combined with a low beta, gives analysts room to argue for multiple expansion alongside earnings growth.
The principal obstacle is policy and regulatory uncertainty. Lawmakers have pressed insurers over Affordable Care Act coverage and PBM practices, and Cigna's Express Scripts unit has been involved in litigation over state prescription-access rules. Cost pressures — including the high expense of GLP-1 weight-loss drugs, which Cigna has moved to limit in its own employee plan — and competitive intensity in managed care are additional headwinds. The recent analyst downgrades from Jefferies and Raymond James, and cautious targets near $300, show that some analysts believe valuation and regulatory risk could keep the shares rangebound below $340.
The 52-week high near $316 is the most relevant resistance level; $340 would require a decisive break above that prior peak. On the downside, the $297–$300 zone has acted as recent support, with the stock holding above its 60-day moving average near $282. The 52-week low sits near $234, underscoring how far the shares have already recovered. In short, the technical structure shows a stock in an uptrend but consolidating after a sharp run toward record levels.
Analyst price targets generally reflect a roughly 12-month horizon, though individual analysts do not always publish an explicit timeframe, so the $340 figure should be read as a forward-looking estimate rather than a precise calendar forecast. The most immediate catalyst is Cigna's third-quarter earnings report, scheduled for November 5, 2026, along with guidance and any commentary on medical-cost trends, Evernorth volumes, and buybacks. Investors should also watch analyst revisions, health-policy developments in Washington, and changes in the stock's reaction near the $316 prior high and $297 support.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders surface opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For investors following CI, this kind of automated signal can complement fundamental research by flagging momentum and technical changes in real time. Explore the AI Daily Buy/Sell Signals to see how it might fit into your own monitoring process.
The $340 target — the mean of verified analyst price targets, with a range of roughly $290 to $400 — implies a substantial 14% advance from about $298. Cigna's earnings growth, Evernorth momentum, buybacks, and undemanding valuation are genuine supports, while regulatory uncertainty, cost pressures, and recent cautious analyst actions are the main obstacles. The wide spread between the low and high targets shows that even professional views diverge sharply, and neither the mean nor any single target is a guarantee. The November 5 earnings report, guidance, and Washington policy developments are the key items to watch before judging whether a move toward $340 is realistic.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CI has been loosely correlated with CVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CI jumps, then CVS could also see price increases.